HC Wainwright Analysts Boost Earnings Estimates for MRKR

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for Marker Therapeutics in a research note issued on Thursday, August 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.16) per share for the quarter, up from their previous forecast of ($0.25). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Marker Therapeutics’ FY2026 earnings at ($0.63) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.85) EPS, FY2029 earnings at ($0.95) EPS and FY2030 earnings at ($1.02) EPS.

Marker Therapeutics (NASDAQ:MRKR) last released its earnings results on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.16. Marker Therapeutics had a negative return on equity of 56.96% and a negative net margin of 343.03%.

Separately, Weiss Ratings upgraded Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Marker Therapeutics Stock Performance

Shares of MRKR opened at $1.52 on Monday. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $2.46. The business’s fifty day moving average is $1.31 and its 200-day moving average is $1.40. The firm has a market cap of $25.34 million, a price-to-earnings ratio of -3.71 and a beta of 1.50.

Hedge Funds Weigh In On Marker Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC acquired a new stake in Marker Therapeutics in the fourth quarter valued at approximately $222,000. XTX Topco Ltd increased its holdings in shares of Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after buying an additional 36,269 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Marker Therapeutics by 16.5% during the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after buying an additional 13,340 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Marker Therapeutics in the 4th quarter valued at $60,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Marker Therapeutics by 16.4% in the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after acquiring an additional 17,400 shares during the last quarter. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.